Comment from AbbVie

Summary: AbbVie supports the FDA's efforts to advance new approach methodologies (NAMs) to reduce reliance on animal testing while requesting specific clarifications on terminology, validation requirements, and submission formats. The company also advocates for more detailed guidance on dose escalation strategies, AI/ML-based models, and pre-submission pathways to ensure regulatory clarity and consistency for sponsors.